|
|
| |
| Determine Frequency of BRCA1 rs1799950 Polymorphism among Sudanese Ovarian Cancer Women
Download PDF
|
Alaa Mubarak Ahmed ELbasheer, Adil Mergani Babikir Hassan, Ibrahim Bakeet Yousif Elemam, Yousif Abdelhameed Mohammed, Abdelraheem Ali Babikir, Randa alginad Mohamed, Wissam Badi Hassan
|
Abstract:
Ovarian cancer (OC) occurs infrequently, but a subset of cases is linked to BRCA1 gene mutations. The ovarian cancer susceptibility gene (BRCA) plays important role in tumor susceptibility. BRCA1 mutations in the germline significantly increase the risk of ovarian cancer and other cancers in women. (1) BRCA1 is a tumor suppressor gene, and its most important action in DNA repair. The aim of the study evaluate the frequency of ( rs1799950) polymorphisms ( In this study determine of one BRCA1 known mutations ( rs1799950 ) in Sudanese women patients with ovarian cancer because suspect effect on risk of cancer). we conducted a case-control population study and spotted that occurrence of rs1799950 -BRCA1 to evaluate the BRCA1 polymorphisms and genetic susceptibility of ovarian cancer among Sudanese women in Gezira state. Overall,85 Ovarian cancer patients attending National Cancer Institute. For control used 65 sample take from normal women do not suffer from any type of cancer and she does not have any family history of cancer, Majority of the ovarian cancer patients were in the age group of <50 years representing 66%, and 34% in age group >50 years. The mean and median age was with age means ( 55.44 ) and ( 56 ) respectively. For all sample case and control make DNA extraction , PCR - CTPP method and gel electrophoresis , to give perfect result. In our study revealed that rs1799950 could related with ovarian cancer risk among Sudanese populations. In this study determine frequency of one BRCA1 known mutations ( rs1799950 ) in Sudanese women patients with ovarian cancer because suspect effect on risk of cancer rare. And, missense variants were detected were found within the study, ( rs1799950) variants were heterozygousone One patient from case group have mutation in BRCAI gene and 4 mutations in control group were detected within postmenopausal patients, with no family history of ovarian cancer.
|
|
|
| | |